NDA 021814 · Boehringer Ingelheim
Aptivus
Tipranavir · Oral
NovelAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jun 22, 2005
Approved uses
3
Original approval plus efficacy supplements
Registered trials
67
14 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 23, 2008 Supplement 5 · Efficacy · priority review ReviewSummary ReviewLetter
- Oct 4, 2007 Supplement 3 · Efficacy LabelLetter
- Jun 22, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- APTIVUS · TIPRANAVIR 250MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tipranavir" as an intervention, any sponsor and status, largest first.
- Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected SubjectsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00146328 · 997 participants · Start Apr 2001 · Primary completion May 2008
Drug: Tipranavir · For: HIV Infections
Sites: Phoenix, Arizona; Berkeley, California; Fountain Valley, California · 233 sites in all
- Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00144170 · 882 participants · Start Feb 2003 · Primary completion Oct 2008
Drug: Tipranavir (with low dose ritonavir); Comparator protease inhibitor(CPI)/low dose ritonavir(r) · For: HIV Infections
Sites: Buenos Aires, Argentina; Vienna, Austria; Antwerp, Belgium · 174 sites in all
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00708162 · 724 participants · Start Jul 2008 · Primary completion Dec 2010
Drug: Elvitegravir; Raltegravir and 3 more · For: HIV Infection
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 180 sites in all
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)Pivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502341 · 689 participants · Start Aug 16, 2022 · Primary completion Sep 29, 2025
Drug: Bictegravir; Lenacapavir and 2 more · For: HIV-1-infection
Sites: Berkeley, California; Beverly Hills, California; Los Angeles, California · 94 sites in all
- Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIVCompleted
Germans Trias i Pujol HospitalAcademic, hospital or other
NCT00307502 · 675 participants · Start Jan 2005 · Primary completion Dec 2009
Drug: Nevirapine; Efavirenz and 9 more · For: HIV Infections
Sites: Badalona, Spain; Figueras, Spain; Granollers, Spain · 6 sites in all
- Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00054717 · 630 participants · Start Jan 2003 · Primary completion Sep 2008
Drug: Tipranavir; Ritonavir(r) and 1 more · For: HIV Infections
Sites: Phoenix, Arizona; Tucson, Arizona; Berkeley, California · 117 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT00144105 · 562 participants · Start Feb 2004 · Primary completion Nov 2006
Drug: TPV500mg/RTV200mgBID; TPV500mg/RTV100mgBID and 1 more · For: HIV Infections
Sites: BsAs, Argentina; Buenos Aires, Argentina; Haedo, Argentina · 81 sites in all
- Optimizing Treatment for Treatment-Experienced, HIV-Infected PeoplePivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00537394 · 517 participants · Start Jan 2008 · Primary completion May 2012
Drug: Enfuvirtide; Raltegravir and 4 more · For: HIV Infections
Sites: Birmingham, Alabama; Long Beach, California; Los Angeles, California · 64 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aptivus (Tipranavir)
2024 spending
$1.1M
Beneficiaries
56
500 claims
Per beneficiary
$18,857
$17.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,013,041 |
| 2021 | $1,661,841 |
| 2022 | $1,438,151 |
| 2023 | $1,283,060 |
| 2024 | $1,056,010 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005.
Toledo T, Oliveira VG, Cattani VB, et al. · Clin Pharmacokinet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.
Elgadi MM, Piliero PJ · Drugs R D 2011 · Comparative Study, Randomized Controlled Trial
- Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
Berhan A, Berhan Y · PLoS One 2013 · Meta-Analysis
- Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.
Garraffo R, Lavrut T, Ferrando S, et al. · J Clin Pharmacol 2011 · Clinical Trial, Controlled Clinical Trial
- Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
Hanley WD, Wenning LA, Moreau A, et al. · Antimicrob Agents Chemother 2009 · Clinical Trial, Research Support, Non-U.S. Gov't
- Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD, Moody DE, Fang WB, et al. · Am J Drug Alcohol Abuse 2011 · Comparative Study, Controlled Clinical Trial
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.